Overactive bladder/enuresis:
Indications for: TOVIAZ
Overactive bladder (OAB) in adults with urge urinary incontinence, urgency, and frequency. Neurogenic detrusor overactivity (NDO) in pediatric patients aged ≥6yrs and weighing >25kg.
Adult Dosage:
Swallow whole with liquid. Initially 4mg once daily; may increase to max 8mg once daily. Severe renal impairment (CrCl<30mL/min) or concomitant strong CYP3A4 inhibitors: max 4mg/day.
Children Dosage:
<6yrs or ≤25kg: not established. Swallow whole with liquid. ≥6yrs (>25–35kg): 4mg once daily, may increase to 8mg once daily if needed; (>35kg): initially 4mg once daily, then increase to 8mg once daily after 1 week. Mild to moderate renal impairment (eGFR 30–89mL/min/1.73m2): (>25–35kg): max 4mg/day; (>35kg): no change (same as above). Severe renal impairment (eGFR 15–29mL/min/1.73m2) or concomitant strong CYP3A4 inhibitors: (>25–35kg): not recommended; (>35kg): max 4mg/day.
TOVIAZ Contraindications:
Urinary or gastric retention. Uncontrolled narrow angle glaucoma.
TOVIAZ Warnings/Precautions:
Significant bladder outlet obstruction, decreased GI motility (eg, severe constipation), severe hepatic impairment: not recommended. Controlled narrow-angle glaucoma. Risk of worsening myasthenia gravis symptoms. Monitor for CNS effects esp. after initiation or dose increases; consider reducing dose or discontinue if occurs. Renal or hepatic impairment. Exposure to high environmental temperatures. Pregnancy. Nursing mothers.
TOVIAZ Classification:
Muscarinic antagonist.
TOVIAZ Interactions:
Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin). Additive effects with other antimuscarinic or anticholinergic agents.
Adverse Reactions:
Dry mouth, constipation; in children: also diarrhea, UTI, abdominal pain, nausea, weight increased, headache; angioedema (discontinue if occurs), CNS effects (eg, headache, dizziness, somnolence).
Generic Drug Availability:
NO
How Supplied:
Tabs—30
